FTEL vs NAUT vs CDNA vs XPOF

For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.

8% revenue growth year-over-year, versus -6. 9% for Fitell Corporation (FTEL). Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Xponential Fitness, Inc.

(XPOF) delivered a total return of -54. 3%, compared to -95. 3% for Fitell Corporation (FTEL). Over 10 years, the gap is even starker: CDNA returned +393. 7% versus FTEL's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fitell Corporation (FTEL) is the lower-risk stock at 1.

19β versus Xponential Fitness, Inc. 's 1. 79β — meaning XPOF is approximately 50% more volatile than FTEL relative to the S&P 500. On balance sheet safety, Fitell Corporation (FTEL) carries a lower debt/equity ratio of 6% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.

8% versus -6. 9% for Fitell Corporation (FTEL). On earnings-per-share growth, the picture is similar: Xponential Fitness, Inc. grew EPS 35. 2% year-over-year, compared to -228. 6% for Fitell Corporation. Over a 3-year CAGR, XPOF leads at 9. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nautilus Biotechnology, Inc.

(NAUT) is the more profitable company, earning 0. 0% net margin versus -208. 5% for Fitell Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -179. 1% for FTEL. At the gross margin level — before operating expenses — XPOF leads at 75. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xponential Fitness, Inc.

(XPOF) trades at 9. 4x forward P/E versus 23. 3x for CareDx, Inc — 13. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XPOF: 25. 0% to $7. 00.

In this comparison, XPOF (2.

9% yield) pays a dividend. FTEL, NAUT, CDNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+393.

7% 10Y return). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +393. 7%, NAUT: -74. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FTEL (Consumer Cyclical) and NAUT (Healthcare) and CDNA (Healthcare) and XPOF (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

XPOF pays a dividend while FTEL, NAUT, CDNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.